Central cardiovascular actions of agmatine, a putative clonidine-displacing substance, in conscious rabbits

Neurochemistry International

Volumn 30, Issue 1, 1997, Pages 37-45

  Head, Geoffrey A ^a   Chan, Candy K S ^a   Godwin, Shirley J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; AGMATINE; ALIPHATIC AMINE; ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; EFAROXAN; IMIDAZOLINE RECEPTOR; METHYLDOPA; MOXONIDINE;

ANIMAL EXPERIMENT; ARTICLE; BRADYCARDIA; BRAIN FOURTH VENTRICLE; CARDIOVASCULAR EFFECT; DOSE RESPONSE; FEMALE; HEART RATE; HYPOTENSION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR AFFINITY;

ADRENERGIC ALPHA-AGONISTS; AGMATINE; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HEART RATE; IMIDAZOLES; MALE; RABBITS; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, DRUG;

EID: 0031025512     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(96)00044-7     Document Type: Article

References (33)

1. Allen, A. M., Guyenet, P. G. (1993) Alpha2-adrenoceptor-mediated inhibition of bulbospinal barosensitive cells of rat rostral medulla. Am. J. Physiol. 265, R1065-R1075.
2. Atlas, D. (1991) Clonidine-displacing substance (CDS) and its putative imidazoline receptor - New leads for further divergence of α2-Adrenergic receptor activity. Biochem. Pharmacol. 41, 1541-1549.
3. Atlas, D. and Burnstein, Y. (1984) Isolation and partial purification of a clonidine displacing substance. Eur. J. Biochem. 144, 287-293.
4. Atlas, D., Diamant, S., Fales, H. M., Pannell, L. (1987) The brain's own clonidine: purification and characterization of endogenous clonidine displacing substance from brain. J. Cardiovasc. Pharmacol. 10, S122-S127.
5. Bousquet, P., Feldman, J. and Atlas, D. (1987) Central cardiovascular effects of a noncatecholamine endogenous ligand for clonidine receptors. J. Cardiovasc. Pharmacol. 10, S167-S171.
6. Bousquet, P., Feldman, J. and Schwartz, J. (1984) Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230, 232-236.
7. Chan, C.K.S., Sannajust, F. and Head, G. A. (1996) Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. J. Pharmacol. Exp. Ther. 276, 411-420.
8. 1-imidazoline sites. J. Pharmacol. Exp. Ther. 264, 172-182.
9. Ernsberger, P., Guiliano, R., Willette, R. N., Reis, D. J. (1990) Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J. Pharmacol. Exp. Ther. 253, 408-418.
10. Ernsberger, P., Meeley, M. P., Reis, D. J. (1988) An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the ventrolateral medulla. Brain Res. 441, 309-318.
11. Feldman, J., Tibirica, E., Bricca, G., Dontenwill, M., Belcourt A. and Bousquet P. (1990) Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br. J. Pharmacol. 100, 600-604.
12. Gomez, R. E., Ernsberger, P., Feinland, G. and Reis, D. J. (1991) Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. Eur. J. Pharmacol. 195, 181-191.
13. Guyenet, P.G., Lynch, K.R., Allen, A.M., Rosin , D.L. and Stornetta R.L. (1993) Alpha2-adrenergic receptors rather than "imidazoline" binding sites mediate the sympatholytic effect of clonidine in the rostral ventrolateral medulla: a new look at the evidence. In Ventral Brainstem Mechanisms and Control Functions, ed. Trouth, Millis, Kiwull-Schoneet et al. Marcel Dekker, Inc., New York.
14. 1-imidazoline receptors in the rostral ventrolateral medulla. J. Cardiovasc. Pharmacol. 24, S1-S8.
15. Head, G. A. (1995) Importance of imidazoline receptors in the cardiovascular actions of centrally acting anti-hypertensive agents. Ann. N.Y. Acad. Sci. 763, 531-540.
16. Head, G. A., Chan, C. K. S. and Sannajust, F. (1994) Role of imidazoline receptors in the central actions of rilmenidine, moxonidine, and clonidine in conscious rabbits. J. Hypertens. 12, S100.
17. Head, G. A., Godwin, S. J., Sannajust, F. (1993) Differential receptors involved in the cardiovascular effects of clonidine and rilmenidine in conscious rabbits. J. Hypertens. 11, S322-S323.
18. Head, G. A., Korner, P. I., Lewis, S. L., Badoer E. (1983) Contribution of noradrenergic and serotonergic neurons to the circulatory effects of centrally acting clonidine and α-methyldopa in rabbits. J. Cardiovasc. Pharmacol. 5, 945-953.
19. Head, G. A., Sannajust, F. (1992) Importance of imidazoline receptors in the cardiovascular responses to clonidine and rilmenidine in conscious rabbits. Fundam. Clin. Pharmacol. 6, S31-S43.
20. Henning, M. and Van Zwieten, P. A. (1968) Central hypotensive effect of alpha-methyldopa. J. Pharm. Pharmacol. 20, 409.
21. 2-adrenoceptors. Br. J. Pharmacol. 110, 1635-1639.
22. Hoffman, W. E., Kochs, E., Werner, C., Thomas, C. and Albrecht, R. F. (1991) Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the α2-adrenergic antagonist atipamezole. Anesthesiology 75, 328-332.
23. Li, G., Regunathan, S., Barrow, C. J., Eshraghi, J., Cooper, R. and Reis D. J. (1994) Agmatine - an endogenous clonidine-displacing substance in the brain. Science 263, 966-969.
24. Mayorov, D., Chernobelski, M. and Medvedev, O. (1993) Sympathoinhibitory action of rilmenidine in conscious sinoaortically denervated rats. J. Cardiovasc. Pharmacol. 22, 314-320.
25. Meeley, M. P., Ernsberger, P. R., Granata, A. R., Reis, D. J. (1986) An endogenous clonidine-displacing substance from bovine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci. 38, 1119-1126.
26. Piletz, J. E., Chikkala, D. N., Ernsberger, P. (1995) Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J. Pharmacol. Exp. Ther. 272, 581-587.
27. Pinthong, D., Wright, I. K., Hanmer, C., Millns, P., Mason, R., Kendall, D. A., Wilson, V. G. (1995) Agmatine recognizes alpha(2)-adrenoceptor binding sites but neither activates nor inhibits alpha(2)-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 10-16.
28. Ruffolo, R. R., Turowski, B. S., Patil, P. N. (1977) Lack of cross desensitization between structurally dissimilar alpha-adrenoceptor agonists. J. Pharm. Pharmacol. 29, 378-380.
29. Sannajust, F. and Head, G. A. (1994) Rilmenidine-induced hypotension involves imidazoline-preferring receptors in conscious rabbits. J. Cardiovasc. Pharmacol. 23, 42-50.
30. Schmitt, H. (1977) The pharmacology of clonidine and related products. In Handbook of Experimental Pharmacology (Gross, Ed.), vol. 39, pp. 1-299. Springer-Verlag, Berlin.
31. Sun, M. K., Regunathan, S. and Reis, D. J. (1995) Cardiovascular responses to agmatine, a clonidine-displacing substance, in anesthetized rat. Clin. Exp. Hypertension 17, 115-128.
32. 2-adrenoceptors. Naunyn Schmiedeberg's Arch. Pharmacol. 348, 593-600.
33. Van Zwieten, P. A. (1988) Pharmacology of the alpha-2 adrenoceptor agonist rilmenidine. Am. J. Cardiol. 61, 6D-14D.